LINC00963 downregulates to enhance carboplatin sensitivity in pancreatic cancer cells, indicating a potential therapeutic target.
LINC00963 downregulation could block PC cell progression and elevate their sensitivity to carboplatin through accelerating miR-495-3p level.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: